new glp 1 agonist for weight loss Hitting the Triple G Spot: The Triple G GLP-1 Agonists: A Comprehensive Overview
Description
DOI: 10.1001/jamanetworkopen.2022.31982
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme
P = 0.04), a main contributor to the reduction of 3-MACE composite endpoint (253)
Rubino, N
Interestingly, the mean values remain relatively normal in most T2DM groups (3133), suggesting that the impaired incretin releases are not a typical prerequisite for the development of T2DM
